Verastem, Inc. (VSTM)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.2300 |
| Open | 1.3000 |
| Bid | 1.2100 x 1400 |
| Ask | 1.3000 x 2200 |
| Day's Range | 1.1920 - 1.3500 |
| 52 Week Range | 1.0000 - 4.9300 |
| Volume | |
| Avg. Volume | 2,355,300 |
| Market Cap | 232.951M |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4110 |
| Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.83 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VSTM
Related Research
- Verastem, Inc.Daily – Vickers Top Buyers & Sellers for 05/16/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat5 days agoArgus Research
- Business Wire
Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer
BOSTON, May 18, 2022--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has received the first "Therapeutic Accelerator Award" from the Pancreatic Cancer Network (PanCAN). The Award will support a Phase 1b/2 clinical trial of the Company’s lead investigational candidates, RAF/MEK Clamp, VS-6766, with FAK inhibitor, defactinib, to evaluate whether a more complete blockade of KRAS signaling, which is
- Business Wire
Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
BOSTON, May 09, 2022--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended March 31, 2022 and highlighted recent progress.
- Zacks
Precision BioSciences (DTIL) Reports Q1 Loss, Misses Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 20.69% and 33.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
